Entero Therapeutics, Inc. (ENTO) delivered a return of 99.30% over the past year. Since ENTO does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Entero Therapeutics, Inc. one year ago would be worth $19,930 today, representing a gain of $9,930.

Entero Therapeutics, Inc. (ENTO) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For ENTO, the total return equals the price-only return.

Yes, Entero Therapeutics, Inc. (ENTO) outperformed the S&P 500 by 78.46 percentage points over the past year. ENTO delivered a total return of 99.30%, compared to the S&P 500's 20.84%. This 78.46pp alpha means investors in ENTO earned more than a passive S&P 500 index fund.

Entero Therapeutics, Inc. (ENTO) experienced a maximum drawdown of -64.39% over the past year, declining from its peak on 2025-10-13 to its trough on 2025-12-18. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Entero Therapeutics, Inc. (ENTO)'s long-term returns with dividends reinvested. Over 10 years, the total return is -100.0% (-70.5% CAGR) — $10,000 would have grown to $0. Over 20 years: -100.0% total return (-45.7% CAGR) — $10,000 → $0. Over 30 years: -100.0% total return (-33.4% CAGR) — $10,000 → $0. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Entero Therapeutics, Inc.'s best calendar year was 2025 with a total return of 140.2%. Its worst year was 2022 with a total return of -98.2%. This range shows the volatility investors should expect — the difference between the best and worst year is 238.4 percentage points.